Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.53 |
| ▸ | CTSB | P07858 | 5/20 | 0.53 |
| ▸ | CTSK | P43235 | 10/20 | 0.52 |
| ▸ | CTSS | P25774 | 5/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496377 | 0.93 | CTSK (0.57) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5488105 | 0.92 | CTSK (0.51) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5490547 | 0.92 | CTSL (0.56) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5494188 | 0.92 | CTSL (0.63) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5491563 | 0.87 | CTSK (0.51) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5492843 | 0.85 | CTSK (0.56) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5495744 | 0.84 | CTSK (0.55) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5493843 | 0.83 | CAPN1 (0.54) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5494980 | 0.82 | CTSK (0.57) | CTSLCTSBCTSKCTSSCAPN1 | |
| SCHEMBL5489802 | 0.81 | CTSK (0.49) | CTSLCTSBCTSKCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1234820-A1 | OXADIAZOLE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | claimed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-01-04 | — | — | US | disclosed |
| US-7144901-B2 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ONO PHARMACEUTICAL CO.,LTD. (JP) | 2006-12-05 | — | — | US | disclosed |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1234820-A1 | OXADIAZOLE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004642-A1 | Oxadiazole derivatives and drugs containing these derivatives as the active ingredient | ACIN1, CYCS, CASP7 | CTSL 302/4885CTSB 231/4885CTSK 280/4885 |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ACIN1, CASP7, ASNS | CTSL 72/4885CTSB 359/4885CTSK 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.